CONMED Co. (NYSE:CNMD) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC increased its holdings in shares of CONMED Co. (NYSE:CNMD - Free Report) by 36.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 110,909 shares of the company's stock after purchasing an additional 29,720 shares during the quarter. Natixis Advisors LLC owned 0.36% of CONMED worth $7,977,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Public Employees Retirement System of Ohio increased its holdings in CONMED by 29.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 47,595 shares of the company's stock valued at $3,811,000 after purchasing an additional 10,736 shares during the last quarter. UniSuper Management Pty Ltd purchased a new stake in shares of CONMED in the 1st quarter valued at $673,000. Kempner Capital Management Inc. acquired a new stake in shares of CONMED during the second quarter worth about $6,480,000. Confluence Investment Management LLC purchased a new position in shares of CONMED in the second quarter valued at approximately $3,526,000. Finally, M&G Plc acquired a new position in shares of CONMED in the second quarter valued at approximately $9,117,000.

Analysts Set New Price Targets

Several brokerages have commented on CNMD. Piper Sandler decreased their price target on shares of CONMED from $95.00 to $80.00 and set an "overweight" rating for the company in a research report on Thursday, August 1st. Stifel Nicolaus lowered their target price on CONMED from $88.00 to $76.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Wells Fargo & Company lowered their price objective on CONMED from $77.00 to $71.00 and set an "equal weight" rating for the company in a research report on Thursday, August 1st. StockNews.com lowered shares of CONMED from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $97.00 price target on shares of CONMED in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, CONMED presently has an average rating of "Moderate Buy" and a consensus price target of $79.80.

CONMED Stock Up 4.5 %

CNMD stock traded up $3.20 during midday trading on Friday, reaching $74.91. 418,779 shares of the company were exchanged, compared to its average volume of 486,432. CONMED Co. has a 1-year low of $61.05 and a 1-year high of $117.27. The company has a market cap of $2.31 billion, a price-to-earnings ratio of 17.79, a price-to-earnings-growth ratio of 0.92 and a beta of 1.45. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.06 and a current ratio of 2.27. The stock's 50-day simple moving average is $69.53 and its 200 day simple moving average is $70.41.

CONMED (NYSE:CNMD - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.06. CONMED had a return on equity of 13.84% and a net margin of 10.23%. The firm had revenue of $316.70 million during the quarter, compared to analysts' expectations of $318.46 million. On average, equities analysts forecast that CONMED Co. will post 4.03 earnings per share for the current year.

CONMED Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.